Wall Street Zen upgraded shares of Athira Pharma (NASDAQ:LONA – Free Report) to a hold rating in a research report released on Saturday,Wall Street Zen reports.
Other research analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a report on Friday, August 7th. Mizuho reduced their price objective on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 19th. Finally, Citizens Jmp decreased their price objective on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating on the stock in a research report on Monday, August 17th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Athira Pharma currently has an average rating of “Moderate Buy” and an average price target of $17.33.
Check Out Our Latest Stock Analysis on Athira Pharma
Athira Pharma Stock Down 1.7%
Shares of NASDAQ:LONA opened at $5.20 on Friday. Athira Pharma has a 52 week low of $2.21 and a 52 week high of $14.21. The stock has a market capitalization of $48.83 million, a P/E ratio of -1.24 and a beta of 2.11. The firm has a fifty day simple moving average of $6.60 and a two-hundred day simple moving average of $8.09.
Athira Pharma (NASDAQ:LONA – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). On average, analysts expect that Athira Pharma will post -2.67 earnings per share for the current year.
About Athira Pharma
Athira Pharma, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines for neurodegenerative diseases and other conditions involving impaired neuronal function. The company’s research has centered on the hepatocyte growth factor (HGF) biological pathway, which is associated with neuronal health, repair and regeneration.
Athira’s lead investigational product was fosgonimeton, also known as ATH-1017, an injectable therapy designed to activate the HGF/MET pathway.
Further Reading
- Five stocks we like better than Athira Pharma
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
